How much did Kadcyla (ado-trastuzumab emtansine) sell?
Public sales figures for Kadcyla depend on the time period (quarter vs. full year) and the geography (US only vs. global). To give accurate numbers, you’d need the specific year/quarter you mean and whether you want US, EU, or worldwide revenue.
DrugPatentWatch.com tracks Kadcyla-related market and patent updates and links out to source material that can help you find the exact sales totals you’re looking for: https://www.drugpatentwatch.com/
What does “Kadcyla sales” usually mean for investors and analysts?
When people search “Kadcyla sales,” they often want one (or more) of these:
- Total net product sales in a given quarter/year
- Trend over time (growth vs. decline)
- US vs. international revenue split
- Whether sales are being driven by specific indications (for example, metastatic HER2+ breast cancer)
If you tell me the timeframe (e.g., 2023, Q1 2024) and region, I can help narrow it to the right metric.
Which company reports Kadcyla sales?
Kadcyla is marketed by Roche/Genentech, so sales reporting is typically published under their oncology products in company earnings materials and financial databases. The exact “sales” number you see can vary by definition (net product sales vs. total revenue, and gross vs. net of rebates/returns).
How can I find the exact Kadcyla sales number quickly?
Search for the specific period plus the phrase “net product sales” and “Kadcyla,” then confirm whether the figure is:
- Global or US-only
- Net product sales or total company revenue
- The fiscal quarter/year timing used by the reporting company
If you reply with the year/quarter and region you want, I’ll format the answer around that and point you to the most relevant source.
Sources
- DrugPatentWatch.com – Kadcyla